SYN News and Press, Synthetic Biologics Inc. From 03/11/22

- Expands pipeline into oncology with unique, clinical-stage oncolytic viruses optimized for intravenous administration - - Strong cash position to support multiple inflection points for VCN-01 with the start of a Phase 2 trial in combination with standard-of-care chemothera...

ROCKVILLE, Md., March 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Wednesday, March...

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference PR Newswire ROCKVILLE, Md. , Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), ...

Synthetic Biologics (NYSE:SYN) said VCN Biosciences' VCN-01 received the U.S. Food & Drug Administration's (FDA) orphan drug designation for retinoblastoma, a type of eye cancer. Synthetic Biologics is in the process of acquiring VCN. "We are highly encouraged by ...

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA Follows recent announcement of planned acquisition of VCN Biosciences by Synthetic Biologics PR Newswire ROCKVILLE, Md. , Feb. 8, 2022 ...

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 PR Newswire ROCKVILLE, Md. , Jan. 26, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing t...

Synthetic Biologics (NYSE:SYN) has added ~2.9% in the pre-market after announcing a definitive agreement to acquire VCN Biosciences, a privately owned clinical-stage immuno-oncology company based in Spain. VCN Biosciences is currently advancing an oncolytic adenovirus (OV) platform ...

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors Lead drug candidate VCN-01 demonstrated clinical activity in multiple Phase 1 clinical trials Design...

Synthetic Biologics, Inc. (SYN) Q3 2021 Earnings Conference Call November 03, 2021, 04:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communications Steven Shallcross - Chief Executive and Financial Officer Michael Kaleko - Senior Vice President-Research and Development V...

Synthetic Biologics (NYSE:SYN): Q3 GAAP EPS of -$0.02 beats by $0.01. Cash and cash equivalents as of September 30, 2021 totaled $72.1 million, an increase of $65.9 million from December 31, 2020. Shares +0.05%. Press Release For further details see: Synthetic Biologics EPS beats by $0....